低位震荡，高人气港股通创新药ETF（520880）溢价不止！机构揭晓七大创新药潜力赛道，“市场空间巨大”！

Group 1 - The Hong Kong Stock Connect innovative drug sector is experiencing volatility, with stocks like MIRXES-B and Tongyuan Kang falling over 10%, and China Biopharmaceuticals down more than 4% [1] - The Hong Kong Stock Connect innovative drug ETF (520880) is fully invested in innovative drug R&D companies and has seen a trading volume exceeding 300 million, with a total of over 600 million raised in the past 11 days [1][4] - The ETF has undergone a "purification" process, removing CXO companies and focusing solely on innovative drug R&D, which is expected to enhance its performance in the market [4][5] Group 2 - A recent report from Kaiyuan Securities highlights seven innovative drug sectors with significant market potential, including next-generation IO, weight loss, and small nucleic acids, which are expected to see positive developments in the next 6-12 months [3] - The report identifies key catalysts and related companies in these sectors, indicating that domestic firms are actively positioning themselves and achieving global leadership in certain areas [3] - The innovative drug ETF (520880) has shown a year-to-date increase of 119.75% prior to the purification revision, outperforming other innovative drug indices [5][6]